Cancer market commentary: Roche’s Tecentriq muscles into NSCLC
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise